Sigma Healthcare has posted a near 34 per cent slide full-year net profit due to $10 million in restructuring, litigation and due diligence costs associated with the recently rejected takeover offer.
Revenue fell 2.9 per cent to $3.98 billion in the year ended January 31, reflecting the $226 million - or a 50 per cent decline in sales - of the low margin Hepatitis C medicines.
Excluding Hepatitis C, revenue was for the period was up 2.9 per cent to $3.75 billion, boosted by growth in Sigma Hospitals and MPS medication management services businesses.
Carrie LaFrenz has the full story here.